Prior Antiplatelet Agent Use and Outcomes after Intravenous Thrombolysis with Recombinant Tissue Plasminogen Activator in Acute Ischemic Stroke: A Meta-Analysis of Cohort Studies and Randomized Controlled Trials

Abstract

Background

There is uncertainty surrounding the influence of prior antiplatelet agent use on outcomes after intravenous thrombolysis with recombinant tissue plasminogen activator in acute ischemic stroke.

Aim

We performed a systematic review with a final meta-analysis to evaluate the efficacy and safety of prior antiplatelet use before intravenous recombinant tissue plasminogen activator for acute ischemic stroke.

Summary of review

We searched PubMed and Embase databases from 1997 to 2014. Primary outcome was functional outcome at the end of follow-up; secondary outcomes were symptomatic intracranial hemorrhage and recanalization rate. The meta-analysis was performed with Review Manager 5·2 (Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012). Eleven studies with a total of 19 453 patients were included. A total of 6517 (33·5%) patients who had received intravenous recombinant tissue plasminogen activator were taking antiplatelet agent before stroke onset. Pooled analysis demonstrated a clear trend that previous anti-platelet users had a reduced probability of good outcome, although it was not conventionally statistically significant (OR 0·86; 95% CI 0·73–1·01; P = 0·06). There was no difference in recanalization rate between two groups (OR 1·23; 95% CI 0·30–4·99; P = 0·77). The risk of symptomatic intracranial hemorrhage was significantly increased in the antiplatelet group (OR 1·65; 95% CI 1·44–1·90; P < 0·01).

Conclusions

In acute ischemic stroke patients receiving intravenous recombinant tissue plasminogen activator therapy, prior antiplatelet agent use did not lead to a significant difference in functional outcome, although it significantly increased the risk of symptomatic intracranial hemorrhage. Recanalization rate was not different between two groups. In the subgroup analysis, prior clopidogrel mono therapy may not increase the risk of symptomatic intracranial hemorrhage, which will need further studies to confirm.

Keywords

acute ischemic stroke antiplatelet agent intravenous thrombolysis meta-analysis

Get full access to this article

View all access options for this article.

References

Jauch

Saver

Adams

Jr . Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2013; 44:870–947.

European Stroke Organisation (ESO) Executive Committee, ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis 2008; 25:457–507.

Sandercock

Wardlaw

Lindley

. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. Lancet 2012; 379:2352–63.

Rha

Saver

. The impact of recanalization on ischemic stroke outcome: a meta-analysis. Stroke 2007; 38:967–73.

Saqqur

Molina

Salam

. Clinical deterioration after intravenous recombinant tissue plasminogen activator treatment: a multicenter transcranial Doppler study. Stroke 2007; 38:69–74.

Multicentre Acute Stroke Trial—Italy (MAST-I) Group. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Lancet 1995; 346:1509–14.

Caplain

Donat

Gaud

Necciari

. Pharmacokinetics of clopidogrel. Semin Thromb Hemost 1999; 25(Suppl. 2):25–8.

Ricci

Lewis

Sandercock

; IST Collaborative Group. Previous use of aspirin and baseline stroke severity: an analysis of 17,850 patients in the International Stroke Trial. Stroke 2006; 37:1737–40.

Šaňák

Kuliha

Herzig

. Prior use of antiplatelet therapy can be associated with a higher chance for early recanalization of the occluded middle cerebral artery in acute stroke patients treated with intravenous thrombolysis. Eur Neurol 2012; 67:52–6.

10.

Uyttenboogaart

Koch

Koopman

Vroomen

De Keyser

Luijckx

. Safety of antiplatelet therapy prior to intravenous thrombolysis in acute ischemic stroke. Arch Neurol 2008; 65:607–11.

11.

Dorado

Millan

De la Ossa

. Influence of antiplatelet pre-treatment on the risk of intracranial haemorrhage in acute ischaemic stroke after intravenous thrombolysis. Eur J Neurol 2010; 17:301–6.

12.

Diedler

Ahmed

Sykora

. Safety of intravenous thrombolysis for acute ischemic stroke in patients receiving antiplatelet therapy at stroke onset. Stroke 2010; 41:288–94.

13.

Bravo

Marti-Fabregas

Cocho

. Influence of antiplatelet pre-treatment on the risk of symptomatic intracranial haemorrhage after intravenous thrombolysis. Cerebrovasc Dis 2008; 26:126–33.

14.

Ibrahim

Sebastian

Hussain

. Does current oral anti-platelet agent or subtherapeutic anticoagulation use have an effect on tissue-plasminogen-activator-mediated recanalization rate in patients with acute ischemic stroke? Cerebrovasc Dis 2010; 30:508–13.

15.

Stang

. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analysis. Eur J Epidemiol 2010; 25:603–5.

16.

Higgins

Thompson

. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21:1539–58.

17.

Frank

Grotta

Alexandrov

. Thrombolysis in stroke despite contraindications or warnings? Stroke 2013; 44:727–33.

18.

Hermann

Dzialowski

Koch

Gahn

. Combined anti-platelet therapy with aspirin and clopidogrel: risk factor for thrombolysis-related intracerebral hemorrhage in acute ischemic stroke? J Neurol Sci 2009; 284:155–7.

19.

Meurer

Kwok

Skolarus

. Does preexisting antiplatelet treatment influence postthrombolysis intracranial hemorrhage in community-treated ischemic stroke patients? An observational study. Acad Emerg Med 2013; 20:146–54.

20.

Tanne

Kasner

Demchuk

. Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke in clinical practice: the Multicenter rt-PA Stroke Survey. Circulation 2002; 105:1679–85.

21.

Zinkstok

Roos

, ARTIS Investigators. Early administration of aspirin in patients treated with alteplase for acute ischaemic stroke: a randomised controlled trial. Lancet 2012; 380:731–7.

22.

Zinkstok

Beenen

Majoie

. Early deterioration after thrombolysis plus aspirin in acute stroke: a post hoc analysis of the antiplatelet therapy in combination with recombinant t-PA thrombolysis in ischemic stroke trial. Stroke 2014; 45:3080–2.

23.

Adams

Jr Del Zoppo

Alberts

. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke 2007; 38:1655–711.